managing cardiovascular risks associated with lifelong tki therapy in cml
Published 1 year ago • 118 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
2:07
the role of the cardio-oncologist in the treatment of patients with hematological malignancies
-
1:03
managing cumulative cardiovascular toxicity associated with btk inhibitors
-
3:08
reducing cardiovascular risk in hypertension with community-based intervention
-
1:10
insights into the influence of cardiovascular toxicity risk on treatment selection in cll
-
1:57
addressing cardiovascular aes associated with btki treatment in patients with cll
-
2:37
reducing the risk of cardiovascular toxicities when treating hematological malignancies
-
2:39
managing the potential cardiotoxicity associated with btkis: important considerations
-
1:04
combining autophagy inhibitors with tkis in cml
-
1:33
the feasibility of tki treatment discontinuation in patients with ph all
-
1:21
cardiovascular adverse events following treatment with btk inhibitors in cll & mcl
-
3:12
addressing cardiotoxicity following car-t therapy and improving clinical practice
-
0:59
mitigating cardiological toxicities associated with btki in b-cell malignancies
-
1:27
preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
-
2:08
improving care in adult patients with leukemia at high-risk of cv adverse events
-
1:24
considerations for tki choice in frontline and r/r cml
-
1:27
managing cardiotoxicity associated with the use of ibrutinib
-
1:20
the current standard of care for patients with lower-risk mds
-
7:50
the esc guidelines on cardio-oncology: incorporating the guidelines into clinical practice
-
4:22
management of btk class driven adverse events